Mylan Upjohn Merger – Pfizer Shareholders to receive 0.12 Viatris Shares per Pfizer Share.

What do Pfizer shareholders get in Mylan deal?

Pfizer’s revenue growth will improve once the Upjohn-Mylan merger wraps up. The big drugmaker will receive a nice $12 billion cash windfall from the deal. Pfizer shareholders will still receive a combined dividend (including a dividend from the new entity formed by the merger) that’s close to what they receive now.

Will Mylan stock become Viatris?

Some 16 months after the deal was announced, generic drugmaker Mylan officially combined with Pfizer Inc.’s Upjohn unit Monday to form a new company called Viatris. The new firm is to begin trading on Nasdaq under the ticker symbol VTRS when the stock market opens Tuesday.

Is the Pfizer spin off taxable?

Pfizer spun off its Upjohn unit which immediately merged with Mylan to form Viatris, effective November 16, 2020 in a transaction meant to be tax-free to Pfizer shareholders. It is structured to be a non-taxable event for Pfizer shareholders. …

Why did I get shares of Viatris?

That’s because Viatris was formed through the merger of Mylan and Upjohn, the generics unit of Pfizer (NYSE:PFE). Pfizer shareholders were given a little more than 12 shares in Viatris for every 100 they held in Pfizer. Mylan shareholders got a Viatris share for every previous Mylan share they held.

Is Viatris a good investment?

One cheap stock worth considering is drugmaker Viatris (NASDAQ:VTRS). It trades at a ridiculously low price-to-earnings ratio of 4.2 and recently announced its first quarterly results and dividend payment. Viatris looks incredibly attractive at these levels, and its business is beginning to show signs of stability.

Why did Mylan stock drop?

Mylan Stock Is Falling Because the Upjohn Deal Won’t Soon Help Earnings, Analyst Says. One of the biggest questions for biopharma investors in 2020 is what to make of the big new generic-drug company being formed by the merger Mylan with Pfizer’s off-patent drug division.

What drugs does Viatris sell?

Products. The company produces and sells a variety of medicines, with 1,400 approved therapeutic molecules in its portfolio. It owns brands (like Viagra, Xanax, Lipitor, generics, including branded and complex generics, biosimilars, and over-the-counter (OTC) drugs and active pharmaceutical ingredients.

What is the cost basis of Viatris?

This results in a tax basis of approximately $4.19 per share, with approximately $519.67 allocated to the 124 shares received of Viatris common stock and approximately $0.33 allocated to the Viatris fractional share in respect of which cash is received.

Is the sale of Mylan a taxable event?

This is a taxable event for Mylan shareholders. It is treated as a sale of Mylan for the value of the Viatris shares received. This is followed by a purchase of the Viatris shares received. The sale proceeds and the total cost of the purchase should be the same in this situation.

Why is Mylan going through a tax inversion?

Mylan is undergoing an “inversion” to reduce their corporate tax liability. The effective rate of taxes Mylan was paying in the United States is not even close to 35%. Shareholders should start planning for tax season. Mylan (NASDAQ:MYL) has gathered a few headlines lately for their inversion with Abbott Laboratories (NYSE:ABT).

What was the effective tax rate for Mylan?

The effective rate of taxes Mylan was paying in the United States is not even close to 35%.

Where do I go to buy Mylan stock?

The Buy Entry Go to Transactions > Buy or Accounting > Securities > Buy depending on the version of the software being used. Here is the information needed for Mylan shareholders to complete the buy portion of the merger. Shares: Is the same as # of Mylan shares owned before merger.